HOME >> BIOLOGY >> NEWS
Clinical trial will test controlled 'drug holidays' to counter HIV

Researchers have received approval for a new clinical trial to test carefully controlled interruptions in HIV patients' drug regimens as an approach to boosting their immune systems, eventually to the point where they can manage their infections without the need for drugs. Patient recruitment will begin immediately for the trial, which was conceived by a team of scientists headed by Luis J. Montaner, D.V.M., D.Phil., an assistant professor at The Wistar Institute, and will be overseen by clinicians in the University of Pennsylvania Health System.

Current state-of-the-art therapy for HIV infection is to administer a cocktail of three drugs that suppresses the virus, often to undetectable levels. While the treatment, known as Highly Active Anti-Retroviral Therapy, or HAART, is very effective, it is too expensive to represent a worldwide solution to the problem of HIV and AIDS. It is also complex and burdensome for patients to adhere to, and it is often accompanied by disturbing, potentially dangerous side effects. While patients are under therapy, however, the number of viruses in their blood drops, and the immune system recovers its ability to respond.

Researchers at The Wistar Institute and elsewhere believe that carefully structured "holidays" from the drugs - known as intermittent HAART - might lead, in effect, to autovaccination against HIV. Patients' ability to mount a response to their own virus has been observed by Dr. Montaner and his colleagues in a subset of chronically infected patients who had maintained long-term viral suppression with their medications before a controlled interruption of treatment. The present trial will test the capacity of these responses to control HIV without medication.

"Many people feel that the answer to AIDS will be found in improved antiviral drugs," says Dr. Montaner, principal investigator on the scientific study that led to development of the new trial. "Immunologists like myself, however, see in the drugs an
'"/>

Contact: Franklin Hoke
hoke@wistar.upenn.edu
215-898-3716
The Wistar Institute
15-May-2000


Page: 1 2

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study reports findings of combination therapy with DOXIL
9. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
10. Clinical trial shows timing of chemotherapy improves survival in breast cancer
11. Clinical services must catch up

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/23/2017)... first robotic gym for the rehabilitation and functional motor sense evaluation of ... Italy . The first 30 robots will be available from June ... . The technology was developed and patented at the IIT laboratories and ... thanks to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/16/2017)... , May 16, 2017   Bridge Patient ... organizations, and MD EMR Systems , an ... partner for GE, have established a partnership to ... product and the GE Centricity™ products, including Centricity ... These new integrations will allow ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
Breaking Biology News(10 mins):
(Date:6/22/2017)... (PRWEB) , ... June 21, 2017 , ... ... regional office in North Carolina, and engages Timothy Reinhardt to manage the new ... quality leadership at Pfizer Inc, with his most recent role as the Director ...
(Date:6/22/2017)... ... June 22, 2017 , ... Ovation Fertility supports the ... disease, bringing new hope for prospective parents who are challenged with costs of ... the World Health Organization’s designation in hopes of changing the way health insurers, ...
(Date:6/22/2017)... ... 2017 , ... The first human cell line HeLa, established in 1951, has ... cross-contamination of human cell lines with HeLa cells were published. Until recently, cross-contamination and ... and is associated with dramatic consequences for research. , In this educational webinar, ...
(Date:6/20/2017)... ... 20, 2017 , ... CTNext , Connecticut’s go-to resource ... a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of the master ... representatives from 35 higher education institutions across the state over the past six ...
Breaking Biology Technology:
Cached News: